{. Afsos, T. Armstrong, P. Wen, and M. Gilbert, Prise en charge de la maladie thromboembolique veineuse en cancérologie Consulté le 14 Mai, 2012, sur ONCOLOR: http://ftp.comm-sante.com {2} AFSSAPS Recommandations de bonne pratique Prévention et traitement de la maladie thromboembolique veineuse en médecine. Consulté le 21 Mars, 2012, sur www.afssaps.fr {3} AMM. (s.d.) Résumé caractéristique du produit Management of treatmentassociated toxicites of anti-angiogenic therapy in patients with brain tumors, Consulté le 9 Mai, 2009.

{. Ay, C. Vormittag, R. Dunkler, and D. , D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study, Journal of Clinical Oncology, vol.27, issue.25, pp.4124-4133, 2009.
DOI : 10.1200/JCO.2008.21.7752

{. Besse, B. Lasserre, S. Compton, and P. , Bevacizumab Safety in Patients with Central Nervous System Metastases, Clinical Cancer Research, vol.16, issue.1, pp.269-78, 2010.
DOI : 10.1158/1078-0432.CCR-09-2439

{. Bigalke, B. Stellos, K. Geisler, and T. , Expression of platelet glycoprotein VI is associated with transient ischemic attack and stroke, European Journal of Neurology, vol.101, issue.1, pp.111-118, 2010.
DOI : 10.1007/s00395-009-0779-7

{. Bokstein, F. Shpigel, S. Et, B. , and D. , Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors, Cancer, vol.23, issue.5 suppl 16, pp.2267-73, 2008.
DOI : 10.1200/JCO.2005.05.098

URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.23401/pdf

{. Brugerolle, B. {10}-callanquin, J. Et, L. , and P. , Les accidents vasculaires cérébraux Les orthèses de série, guide à l'usage des praticiens, Consulté le 16 Mai, 1996.

{. Cemv, A. Choucair, P. Silver, and V. Levin, Accidents Vasculaires Cérébraux (AVC) Consulté le 16 Mai, 2012, sur http://cemv.vascular-e-learning Risk of intracranial hemorrhage in glioma patients receiving anticoagulant therapy for venous thromboembolism, J Neurosurg, issue.3, pp.66357-66365, 1987.

{. Crino, L. Dansin, E. Garrido, and P. , Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study, The Lancet Oncology, vol.11, issue.8, pp.11733-11773, 2010.
DOI : 10.1016/S1470-2045(10)70151-0

{. Dansin, E. Cinieri, S. Garrido, and P. , MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC, Lung Cancer, vol.76, issue.3, pp.76373-76382, 2012.
DOI : 10.1016/j.lungcan.2011.11.020

{. De-braganca, K. Janjigian, Y. Azzoli, and C. , Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer, Journal of Neuro-Oncology, vol.4, issue.3, pp.443-450, 2010.
DOI : 10.1007/s11060-010-0200-2

{. Dhami and M. B. , Venous thromboembolism and high grade gliomas, Thromb Haemost, vol.70, issue.3, pp.393-399, 1993.

{. Dranitsaris, G. Edwards, S. Edwards, and J. , Bevacizumab in combination with FOLFIRI chemotherapy in patients with metastatic colorectal cancer: an assessment of safety and efficacy in the province of Newfoundland and Labrador, Current Oncology, vol.17, issue.5, pp.12-18, 2010.
DOI : 10.3747/co.v17i5.592

{. Elalamy and I. , Avis d'expert en oncologie : Maladie Thrombo-embolique Veineuse et pathologie cancéreuse, 2008.

{. Elice, F. Jacoub, J. Rickles, and F. , Hemostatic complications of angiogenesis inhibitors in cancer patients, American Journal of Hematology, vol.25, issue.11, pp.862-70, 2008.
DOI : 10.3748/wjg.v11.i14.2166

{. Elice, F. Rodeghiero, F. Falanga, and A. , Thrombosis associated with angiogenesis inhibitors, Best Practice & Research Clinical Haematology, vol.22, issue.1, pp.115-143, 2009.
DOI : 10.1016/j.beha.2009.01.001

{. Eusi, {. Org, P. Ferroni, V. Formica, and M. Roselli, AVC ischémique Prévention et traitement Information pour médecin hospitalier et libéraux Consulté le 12 Mars, 2012, sur http://www.eso-stroke Thromboembolic events in patients treated with anti-angiogenic drugs, Curr Vasc Pharmacol, vol.8, issue.1, pp.102-115, 2003.

{. Figarella-branger, D. Et, B. , and C. , Histological classification of human gliomas: state of art and controversies, Bull Cancer, vol.92, issue.4, pp.301-310, 2005.

{. Flynn, P. Sugrue, M. Feng, and S. , Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS), Journal of Clinical Oncology, vol.26, issue.15_suppl, p.20, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.4104

{. Fraum, T. Kreisl, T. Sul, and J. , Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy, Journal of Neuro-Oncology, vol.96, issue.2, pp.281-290, 2011.
DOI : 10.1038/sj.bjc.6603813

{. Friedman, H. Prados, M. Wen, and P. , Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma, Journal of Clinical Oncology, vol.27, issue.28, pp.4733-4773, 2009.
DOI : 10.1200/JCO.2008.19.8721

{. Gerber, D. Grossman, S. Et, S. , and M. , Management of Venous Thromboembolism in Patients With Primary and Metastatic Brain Tumors, Journal of Clinical Oncology, vol.24, issue.8, pp.1310-1318, 2006.
DOI : 10.1200/JCO.2005.04.6656

{. Giantonio, B. Catalano, P. Meropol, and N. , Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200, Journal of Clinical Oncology, vol.25, issue.12, pp.251539-251583, 2007.
DOI : 10.1200/JCO.2006.09.6305

{. Gilbert, M. Wang, M. Aldape, and K. , A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM), Neuro-Oncology, pp.36-57, 2010.

{. Gordon, M. Margolin, K. Talpaz, and M. , Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer, Journal of Clinical Oncology, vol.19, issue.3, pp.843-850, 2001.
DOI : 10.1200/JCO.2001.19.3.843

{. Grillo, P. Velly, L. Et, B. , and N. , Accident vasculaire c??r??bral h??morragique??: nouveaut??s sur??la??prise en??charge, Annales Fran??aises d'Anesth??sie et de R??animation, vol.25, issue.8, pp.25868-73, 2006.
DOI : 10.1016/j.annfar.2006.03.030

{. Hambleton, J. Novotny, W. Hurwitz, and H. , Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation, ASCO Annual Meeting Proceedings, p.223528, 2004.

{. Hambleton, J. Skillings, J. Kabbinavar, and F. , Safety of lowdose aspirin in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer, J Clin Oncol, issue.Suppl16S, p.233554, 2005.

{. Hang, X. Xu, W. Wang, and J. , Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials, European Journal of Clinical Pharmacology, vol.309, issue.6, 2011.
DOI : 10.1136/bmj.309.6965.1351

{. Hapani, S. Et, W. , and S. , Controversial Role of Bevacizumab in the Development of Venous Thromboembolic Events, Journal of Clinical Oncology, vol.29, issue.25, p.293490, 2011.
DOI : 10.1200/JCO.2011.36.5478

{. Hapani, S. Sher, A. Chu, and D. , Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis, Oncology, vol.79, issue.1-2, pp.27-38, 2010.
DOI : 10.1159/000314980

{. Has, . {38}, J. Hildebrand, C. Lecaille, and J. Perennes, Recommandations de bonnes pratiques Accident vasculaire cérébral, prise en charge précoce (alerte, phase préhospitalière, phase hospitalière initiale,indications de la thrombolyse) Consulté le 21 Mars, 2012, sur http Epileptic seizures during follow-up of patients treated for primary brain tumors, Neurology, issue.2, pp.65212-65217, 2005.

{. Hogh, A. Joensen, J. Lindholt, and J. , C-Reactive Protein Predicts Future Arterial and Cardiovascular Events in Patients With Symptomatic Peripheral Arterial Disease, Vascular and Endovascular Surgery, vol.152, issue.4, pp.341-348, 2008.
DOI : 10.1002/bjs.1800811111

{. Hottinger, A. Et, S. , and R. , Strat??gies th??rapeutiques pour le traitement des gliomes, Revue Neurologique, vol.164, issue.6-7, pp.523-553, 2008.
DOI : 10.1016/j.neurol.2008.03.012

{. Hurwitz, H. Fehrenbacher, L. Novotny, and W. , Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.350, issue.23, pp.3502335-3502377, 2004.
DOI : 10.1056/NEJMoa032691

{. Hurwitz, H. Saltz, L. Vancustem, and E. , Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies, Journal of Clinical Oncology, vol.29, issue.13, pp.291757-64, 2011.
DOI : 10.1200/JCO.2010.32.3220

{. Jenkins, E. Schiff, D. Mackman, and N. , Venous thromboembolism in malignant gliomas, Journal of Thrombosis and Haemostasis, vol.10, issue.Suppl., pp.221-227, 2010.
DOI : 10.1128/MCB.19.3.2032

{. Kabbinavar, F. Hambleton, J. Mass, and R. , Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.23, issue.16, pp.233706-233718, 2005.
DOI : 10.1200/JCO.2005.00.232

{. Kabbinavar, F. Hurwitz, H. Fehrenbacher, and L. , Phase II, Randomized Trial Comparing Bevacizumab Plus Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.21, issue.1, pp.60-65, 2003.
DOI : 10.1200/JCO.2003.10.066

{. F. Keime-guibert, O. Chinot, and L. Taillandier, Radiotherapy for Glioblastoma in the Elderly, New England Journal of Medicine, vol.356, issue.15, pp.1527-1562, 2007.
DOI : 10.1056/NEJMoa065901

{. Khorana and A. , Risk Assessment and Prophylaxis for VTE in Cancer Patients, Journal of the National Comprehensive Cancer Network, vol.9, issue.7, pp.789-97, 2011.
DOI : 10.6004/jnccn.2011.0064

{. Kreisl, T. Kim, L. Moore, and K. , Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma, Journal of Clinical Oncology, vol.27, issue.5, pp.740-745, 2009.
DOI : 10.1200/JCO.2008.16.3055

{. Lai, A. Filka, E. Mcgibbon, and B. , Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability, Int J Radiat Oncol Biol Phys, issue.5, pp.711372-80, 2008.

{. Lai, A. Tran, A. Nghiemphu, and P. , Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme, Journal of Clinical Oncology, vol.29, issue.2, pp.142-150, 2011.
DOI : 10.1200/JCO.2010.30.2729

{. Leighl, N. Bennouna, J. , Y. , and J. , Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study, British Journal of Cancer, vol.350, issue.3, pp.413-421, 2011.
DOI : 10.1200/JCO.2007.12.2440

{. Levin, V. Bidaut, L. Hou, and P. , Randomized double-blind placebocontrolled trial of bevacizumab therapy for radiation necrosis of the central nervous system, Int J Radiat Oncol Biol Phys, issue.5, pp.791487-95, 2011.

{. Lin, J. Proctor, M. Varma, and M. , Factors associated with recurrent venous thromboembolism in patients with malignant disease, Journal of Vascular Surgery, vol.37, issue.5, pp.976-83, 2003.
DOI : 10.1067/mva.2003.191

{. Marras, L. Geerts, W. Et, P. , and J. , The risk of venous thromboembolism is increased throughout the course of malignant glioma, Cancer, vol.27, issue.3, pp.640-646, 2000.
DOI : 10.1227/00006123-199007000-00010

{. Menevau and N. , Thrombose veineuse profonde des membres inférieurs, étiologie, physiopathologie, diagnostic, évolution, pronostic et traitement, 2001.

{. Org and N. Meneveau, L'embolie pulmonaire, étiologie, physiopathologie, diagnostic, évolution, pronostic et traitement Management of toxicity in patients receiving therapy with bevacizumab, Mars Eurpean journal of cancer supplements, vol.6, issue.suppl6, pp.29-39, 2001.

{. Moheimani, F. Et, J. , and D. , Venous Thromboembolism: Classification, Risk Factors, Diagnosis, and Management, ISRN Hematology, vol.153, issue.9, p.124610, 2011.
DOI : 10.1111/j.1538-7836.2007.02657.x

{. Montaner, J. Perea-gainza, M. Delgado, and P. , Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers, Stroke, vol.39, issue.8, pp.392280-392287, 2008.
DOI : 10.1161/STROKEAHA.107.505354

{. Nalluri, S. Chu, D. Keresztes, and R. , Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients, JAMA, vol.300, issue.19, pp.3002277-85, 2008.
DOI : 10.1001/jama.2008.656

{. Nci and P. G. , Critères d'évaluation de la morbbidité aigüeselon la clasiification du NationalCancer Institute Safety of anticoagulation use and bevacizumab in patients with glioma, Neuro Oncol, vol.10, issue.3, pp.355-60, 2008.

{. Nomura, H. Wada, H. Mizuno, and T. , Elevated Fibrin-Related Markers in Patients with Malignant Diseases Suspected of Having Thrombotic Disorders, Clinical and Applied Thrombosis/Hemostasis, vol.71, issue.2, pp.266-72, 2010.
DOI : 10.1002/ajh.2830440208

{. Norden, A. Bartolomeo, J. Tanaka, and S. , Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients, Journal of Neuro-Oncology, vol.27, issue.1, pp.121-126, 2011.
DOI : 10.1200/JCO.2008.16.3055

{. Norden, A. Drappatz, J. Et, W. , and P. , Novel anti-angiogenic therapies for malignant gliomas, The Lancet Neurology, vol.7, issue.12, pp.1152-60, 2008.
DOI : 10.1016/S1474-4422(08)70260-6

{. Oncolor, {. Oncologiedeladulte, E. Pan, J. Tsai, M. Et et al., Référentiel neurooncologie de l'adulte. Consulté le 16 Mai, 2012, sur https://sites.google.com/a/esante-picardie.com/oncopic Retrospective Study of Venous Thromboembolic and Intracerebral Hemorrhagic Events in Glioblastoma Patients, Anticancer research, vol.29, issue.2, pp.4309-4314, 2009.

{. Perry and J. , Anticoagulation of malignant glioma patients in the era of novel antiangiogenic agents, Current Opinion in Neurology, vol.23, issue.6, pp.592-598, 2010.
DOI : 10.1097/WCO.0b013e32833feb73

{. Perry, J. Julian, J. Laperriere, and N. , PRODIGE: a randomized placebo-controlled trial of dalteparin low molecular weight, J Thromb Haemost, p.252011, 2010.

{. Posner and J. , Neurologic complications of cancer, 1995.

{. Prados and M. L. , A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study1, Neuro-Oncology, vol.8, issue.2, pp.189-93, 2006.
DOI : 10.1093/annonc/mdg159

{. Psimaras, D. Et, D. , and J. , Perspectives dans le diagnostic et la prise en charge des gliomes malins, Cancer/Radioth??rapie, vol.12, issue.6-7, pp.695-700, 2008.
DOI : 10.1016/j.canrad.2008.09.006

{. Ramacciotti, E. Blackburn, S. Hawley, and A. , Evaluation of Soluble P-Selectin as a Marker for the Diagnosis of Deep Venous Thrombosis, Clinical and Applied Thrombosis/Hemostasis, vol.82, issue.6, pp.425-456, 2011.
DOI : 10.1016/j.thromres.2009.12.012

{. Ranpura, V. Hapani, S. Chuang, and J. , Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials, Acta Oncologica, vol.36, issue.15, pp.49287-97, 2010.
DOI : 10.1200/JCO.2007.15.6331

{. Rectenwald, J. Myers, D. Hawley, and A. , D-dimer, P-selectin, and microparticles: Novel markers to predict deep venous thrombosis. A pilot study, Thrombosis and Haemostasis, issue.6, pp.941312-941319, 2005.
DOI : 10.1160/TH05-06-0426

{. Ruff, R. Et, P. , and J. , Incidence and treatment of peripheral venous thrombosis in patients with glioma, Annals of Neurology, vol.303, issue.3, pp.334-340, 1983.
DOI : 10.1212/WNL.27.5.435

{. Scappaticci, F. Skillings, J. Holden, and S. , Arterial Thromboembolic Events in Patients with Metastatic Carcinoma Treated with Chemotherapy and Bevacizumab, JNCI Journal of the National Cancer Institute, vol.292, issue.15, pp.991232-991241, 2007.
DOI : 10.1001/jama.292.15.1867

{. Schiff, D. Et, D. , and L. , Therapy of venous thromboembolism in patients with brain metastases, Cancer, vol.79, issue.2, pp.493-501, 1994.
DOI : 10.1148/radiology.185.1.1523320

{. Schiff, D. Et, W. , and P. , Cancer neurology in clinical practice, 2003.

{. Schutz, F. Je, Y. Azzi, and G. , Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes, Annals of Oncology, vol.7, issue.1, pp.221404-221416, 2011.
DOI : 10.1111/j.1538-7836.2008.03212.x

{. Schved, J. F. Fr, {. Seet, R. Rabinstein, A. Lindell et al., Physiologie de l'hémostase.Consulté le 5 mars, 2012, sur http.med.univ.-montp1 Cerebrovascular events after bevacizumab treatment: an early and severe complication, Neurocrit Care, vol.15, issue.3, pp.421-428, 2007.

{. Senellart, H. Et, B. , and J. , Thrombo-embolic risks and bevacizumab: data from the literature and recommendations for the use of anticoagulants and antiaggregants, Revue des maladies respiratoires, issue.8, pp.251027-251057, 2008.

{. Shah, M. Ilson, D. Et, K. , and D. , Thromboembolic Events in Gastric Cancer: High Incidence in Patients Receiving Irinotecan- and Bevacizumab-Based Therapy, Journal of Clinical Oncology, vol.23, issue.11, pp.2574-2580, 2005.
DOI : 10.1200/JCO.2005.81.908

{. Shord, S. Bressler, L. Tierney, and L. , Understanding and managing the possible adverse effects associated with bevacizumab, American Journal of Health-System Pharmacy, vol.66, issue.11, pp.66999-1013, 2009.
DOI : 10.2146/ajhp080455

{. Socinski, M. Langer, C. Huang, and J. , Safety of Bevacizumab in Patients With Non???Small-Cell Lung Cancer and Brain Metastases, Journal of Clinical Oncology, vol.27, issue.31, pp.275255-61, 2009.
DOI : 10.1200/JCO.2009.22.0616

{. Stark-vance and V. , Bevacizumab and CPT-11 in the treatemnt of relapsed, Neuro-Oncology, vol.7, p.369, 2005.

{. Stupp, R. Pica, A. Mirimanoff, and R. , A pratical guide for the management of gliomas, Bull Cancer, vol.94, pp.817-839, 2007.

{. Suenaga, M. Mizunuma, N. Kobayashi, and K. , Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab, Medical Oncology, vol.152, issue.6, pp.807-821, 2010.
DOI : 10.1161/01.ATV.20.6.1512

{. Sugrue, M. Kozloff, M. Hainsworth, and J. , Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: Results from the BRiTE registry, J Clin Oncol, issue.Suppl18S, p.25345, 2007.

{. Taillibert, S. Pedretti, M. Et, S. , and M. , Classification actuelle des gliomes, La Presse M??dicale, vol.33, issue.18, pp.1274-1281, 2004.
DOI : 10.1016/S0755-4982(04)98906-3

{. Takahashi, S. Yazaki, T. Nitori, and N. , Neuroendoscope-Assisted Removal of an Organized Chronic Subdural Hematoma in a Patient on Bevacizumab Therapy, Neurologia medico-chirurgica, vol.51, issue.7, pp.51515-51523, 2011.
DOI : 10.2176/nmc.51.515

{. Tebbutt, N. Murphy, F. Zannino, and D. , Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab, Annals of Oncology, vol.22, issue.1, pp.221834-221842, 2011.
DOI : 10.1016/j.beha.2009.01.001

{. Theriaque, {. Org, K. Vahedi, E. Vicaut, and J. Mateo, Thériaque Consulté le 9 mai, 2012, sur http://www.theriaque Sequential-design,multicenter, randomized, controlled trial of early decompressive craniectomy in malignant middle cerebral artery infarction (DECIMAL Trial), Stroke, issue.9, pp.382506-382507, 2007.

{. Vargo and J. S. , Dural venous sinus thrombosis in anaplastic astrocytoma following concurrent temozolomide and focal brain radiotherapy plus bevacizumab, Journal of Neuro-Oncology, vol.54, issue.2, pp.595-603, 2011.
DOI : 10.1212/WNL.54.6.1222

{. Vredenburgh, J. Desjardins, and A. Herndon, Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme, Journal of Clinical Oncology, vol.25, issue.30, pp.254722-254731, 2007.
DOI : 10.1200/JCO.2007.12.2440

{. Wen, P. Et, K. , and S. , Malignant Gliomas in Adults, New England Journal of Medicine, vol.359, issue.5, pp.492-507, 2008.
DOI : 10.1056/NEJMra0708126

{. Wen, P. Schiff, D. Kesari, and S. , Medical management of patients with brain tumors, Journal of Neuro-Oncology, vol.94, issue.3, pp.313-345, 2006.
DOI : 10.1016/S0025-6196(12)62216-2

{. Wen, P. , Y. , W. Et, L. et al., Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08, Clinical Cancer Research, vol.12, issue.16, pp.99-107, 2006.
DOI : 10.1158/1078-0432.CCR-06-0773

{. Yasuoka, S. Et, K. , and S. , The value of blood D-dimer test in the diagnosis of walk-in patients with venous thromboembolism, Vasc Health Risk Manag, vol.7, pp.125-132, 2011.

{. Zandecki and M. , Physiologie de la coagulation, Consulté le 5 Mars, 2006.